Quick Answer
BridgeBio Pharma, Inc. reported Total Assets of $936.02 million for fiscal year 2025.
BridgeBio Pharma, Inc. Total Assets — Annual History
| Fiscal Year | Total Assets | YoY Change |
|---|---|---|
| 2025 | $936.02M | +1.8% |
| 2024 | $919.34M | +68.3% |
| 2023 | $546.38M | -12.3% |
| 2022 | $623.04M | -38.5% |
| 2021 | $1.01B | +43.9% |
| 2020 | $703.59M | +11.4% |
| 2019 | $631.68M | +35.9% |
| 2018 | $464.94M | — |
Quarterly Total Assets
| Quarter Ending | Total Assets | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $998.25M | +50.1% | -7.6% |
| June 30, 2025 | $1.08B | +36.0% | +22.5% |
| March 31, 2025 | $881.64M | +3.8% | -4.1% |
| December 31, 2024 | $919.34M | +68.3% | +38.3% |
| September 30, 2024 | $664.98M | +1.5% | -16.3% |
| June 30, 2024 | $794.38M | +57.7% | -6.5% |
| March 31, 2024 | $849.33M | +35.7% | +55.4% |
| December 31, 2023 | $546.38M | -12.3% | -16.6% |
- BridgeBio Pharma, Inc. showed an increase of +1.8% in Total Assets compared to the prior fiscal year.
- Over the 2018–2025 period, BridgeBio Pharma, Inc.’s total assets has grown by 101.3% (from $464.94 million to $936.02 million).
- The most recent figure is from BridgeBio Pharma, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 24, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: